Cytokinetics Inc 8-K Filing
Ticker: CYTK · Form: 8-K · Filed: Nov 14, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Nov 14, 2025 |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $660,000, $400,000, $5,800,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cytokinetics Inc (ticker: CYTK) to the SEC on Nov 14, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se); $660,000 ('s annual base salary will initially be $660,000, and he will be entitled to participate); $400,000 (el will also be paid a signing bonus of $400,000, 50% of which is payable upon the close); $5,800,000 (stock units with a grant date value of $5,800,000 (based on the closing price of the Comp).
How long is this filing?
Cytokinetics Inc's 8-K filing is 4 pages with approximately 1,347 words. Estimated reading time is 5 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,347 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2025-11-14 16:05:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
- $660,000 — 's annual base salary will initially be $660,000, and he will be entitled to participate
- $400,000 — el will also be paid a signing bonus of $400,000, 50% of which is payable upon the close
- $5,800,000 — stock units with a grant date value of $5,800,000 (based on the closing price of the Comp
Filing Documents
- cytk-20251113.htm (8-K) — 47KB
- 0001193125-25-282889.txt ( ) — 152KB
- cytk-20251113.xsd (EX-101.SCH) — 24KB
- cytk-20251113_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: November 14, 2025 By: /s/ John O. Faurescu John O. Faurescu SVP, Deputy General Counsel & Secretary